Table 3. Abnormal Laboratory Findings for Patients with Laboratory-Confirmed Chikungunya Virus Infection (n = 180), Compared with Chikungunya Virus-Negative Patients (n = 72)—Veterans Health Administration, 2014.
| CHIKV-positive | CHIKV-Negative | P Value | |
|---|---|---|---|
| Leukopenia (n = 239), no. (%) | 64 (37.0) | 15 (22.7) | .04 |
| WBC on presentation (n = 78), mean ± SD, cells ×103/μL | 4.6 ± 1.4 | 5.3 ± 3.8 | |
| WBC nadir (n = 79), mean ± SD, cells ×103/μL | 2.9 ± 0.6 | 3.0 ± 0.7 | |
| Lymphopenia (n = 234), no. (%) | 122 (71.4) | 24 (38.1) | < .0001 |
| ALC on presentation (n = 145), mean ± SD, cells ×103/μL | 0.6 ± 0.3 | 0.7 ± 0.2 | |
| ALC nadir (n = 146), mean ± SD cells ×103/μL | 0.6 ± 0.2 | 0.6 ± 0.2 | |
| Thrombocytopenia (n = 239), no. (%) | 80 (46.5) | 28 (41.8) | .51 |
| Platelet count on presentation (n = 106), mean ± SD, ×103cells/μL | 121 ± 35 | 121 ± 39 | |
| Platelet count nadir (n = 108), mean ± SD, ×103cells/μL | 104 ± 31 | 93 ± 39 | |
| Acute kidney injurya (n = 213), no. (%) | 33 (21.6) | 9 (15.0) | .28 |
| Stage I | 23 (69.7) | 8 (88.9) | |
| Stage II | 6 (18.2) | 0 (0) | |
| Stage III | 4 (12.1) | 1 (11.1) | |
| Hepatic transaminitis (n = 184), no. (%) | 52 (40.3) | 23 (41.8) | .85 |
| 1–2 × ULN | 29 (55.8) | 10 (43.5) | |
| 2–3 × ULN | 7 (13.5) | 8 (34.8) | |
| >3 × ULN | 16 (30.8) | 5 (21.7) |
CHIKV, chikungunya virus; WBC, white blood cell count; SD, standard deviation; ALC, absolute lymphocyte count; and ULN, upper limit of normal.
aAcute kidney injury stage I, increase in serum creatinine by ≥0.3 mg/dL or 26.5 μmol/L from baseline (last creatinine); stage II, 2.0–2.9 × baseline; and stage III, ≥3.0 × baseline [28].